1. Home
  2. CLLS vs NAKA Comparison

CLLS vs NAKA Comparison

Compare CLLS & NAKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CLLS
  • NAKA
  • Stock Information
  • Founded
  • CLLS 1999
  • NAKA 2019
  • Country
  • CLLS France
  • NAKA United States
  • Employees
  • CLLS N/A
  • NAKA N/A
  • Industry
  • CLLS Biotechnology: Pharmaceutical Preparations
  • NAKA
  • Sector
  • CLLS Health Care
  • NAKA
  • Exchange
  • CLLS Nasdaq
  • NAKA Nasdaq
  • Market Cap
  • CLLS 299.0M
  • NAKA 347.4M
  • IPO Year
  • CLLS 2007
  • NAKA 2024
  • Fundamental
  • Price
  • CLLS $3.22
  • NAKA $0.78
  • Analyst Decision
  • CLLS Buy
  • NAKA Strong Buy
  • Analyst Count
  • CLLS 1
  • NAKA 2
  • Target Price
  • CLLS $8.00
  • NAKA $5.00
  • AVG Volume (30 Days)
  • CLLS 134.5K
  • NAKA 31.4M
  • Earning Date
  • CLLS 11-07-2025
  • NAKA 11-05-2025
  • Dividend Yield
  • CLLS N/A
  • NAKA N/A
  • EPS Growth
  • CLLS N/A
  • NAKA N/A
  • EPS
  • CLLS N/A
  • NAKA N/A
  • Revenue
  • CLLS $63,438,000.00
  • NAKA $2,239,936.00
  • Revenue This Year
  • CLLS N/A
  • NAKA N/A
  • Revenue Next Year
  • CLLS $58.00
  • NAKA $2,755.19
  • P/E Ratio
  • CLLS N/A
  • NAKA N/A
  • Revenue Growth
  • CLLS 223.09
  • NAKA N/A
  • 52 Week Low
  • CLLS $1.10
  • NAKA $0.65
  • 52 Week High
  • CLLS $5.48
  • NAKA $34.77
  • Technical
  • Relative Strength Index (RSI)
  • CLLS 41.41
  • NAKA 34.88
  • Support Level
  • CLLS $3.12
  • NAKA $0.78
  • Resistance Level
  • CLLS $3.79
  • NAKA $0.98
  • Average True Range (ATR)
  • CLLS 0.19
  • NAKA 0.11
  • MACD
  • CLLS -0.08
  • NAKA 0.14
  • Stochastic Oscillator
  • CLLS 13.43
  • NAKA 25.86

About CLLS Cellectis S.A.

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

About NAKA Kindly MD Inc. Common Stock

Kindly MD Inc is a holistically focused pain management clinic and healthcare data company. It offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Its specialty outpatient clinical services are offered on a subscription and fee-for-service basis to augment traditional healthcare. The Company offers evaluation and management, including, but not limited to chronic pain, functional medicine, cognitive behavioral therapy, recovery support services, overdose education efforts, peer support, limited urgent care, preventative medicine, travel services, and hormone therapy.

Share on Social Networks: